Supplemental material
Journal of Dermatological Treatment
Volume 33, 2022 - Issue 4
Articles
Efficacy, safety, usability, and acceptability of risankizumab 150 mg formulation administered by prefilled syringe or by an autoinjector for moderate to severe plaque psoriasis
Andrew Blauvelta Oregon Medical Research Center, Portland, OR, USACorrespondence[email protected]
https://orcid.org/0000-0002-2633-985XView further author information
https://orcid.org/0000-0002-2633-985XView further author information, , , , Howard Sofene Department of Medicine/Dermatology, UCLA School of Medicine, Los Angeles, CA, USAhttps://orcid.org/0000-0001-7789-6915View further author information
https://orcid.org/0000-0001-7789-6915View further author information, , , , Tianyu Zhani AbbVie Inc., North Chicago, IL, USAhttps://orcid.org/0000-0002-8572-4539View further author information
https://orcid.org/0000-0002-8572-4539View further author information, & Linda Stein Goldk Henry Ford Health System, Detroit, MI, USAhttps://orcid.org/0000-0002-2758-1605View further author information
https://orcid.org/0000-0002-2758-1605View further author information show allRelated Research Data
Efficacy, safety, usability, and acceptability of risankizumab 150 mg formulation administered by prefilled syringe or by an autoinjector for moderate to severe plaque psoriasis
Source:
Taylor & Francis
Linking provided by
